Branded Generics Market Size, Share, Trends, Growth Outlook

Branded Generics Market is estimated to increase at a growth rate of 6.3% CAGR over the forecast period from 2024 to 2030.

The Branded Generics Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Others), By Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Gastrointestinal Diseases, Dermatological Diseases, Acute and Chronic Pain, Others), By Route of Administration (Topical, Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy).

An Introduction to Branded Generics Market in 2024

The Branded Generics market in 2024 represents a hybrid segment of the pharmaceutical industry, offering affordable yet quality-assured generic medications under recognizable brand names. Branded generics combine the cost-effectiveness of generic drugs with the brand equity and trust associated with established pharmaceutical brands. Market dynamics are shaped by factors such as patent expirations, generic competition, and healthcare policies promoting generic substitution. Collaboration between generic manufacturers, regulatory authorities, and healthcare providers drives innovation in branded generics, ensuring compliance with quality standards and enhancing patient access to essential medications across therapeutic categories.

Branded Generics Market Trend: Increasing Preference for Branded Generics

A prominent trend in the Branded Generics market is the increasing preference for branded generic drugs among consumers and healthcare providers. Branded generics offer a balance between affordability and quality, providing the assurance of a known brand while being more cost-effective than innovator brands. This trend is driven by factors such as patent expirations of originator drugs, rising healthcare costs, and growing acceptance of generic medications among patients and physicians.

Branded Generics Market Driver: Cost Containment Measures in Healthcare

The primary driver for the Branded Generics market is the implementation of cost containment measures in healthcare systems worldwide. Governments, insurers, and healthcare providers are increasingly focusing on reducing healthcare expenditures while maintaining quality and access to essential medications. Branded generics offer a cost-effective alternative to both originator brands and generic drugs, making them attractive options for healthcare stakeholders seeking to optimize healthcare spending without compromising patient care.

Branded Generics Market Opportunity: Market Expansion in Emerging Economies

An opportunity in the Branded Generics market lies in market expansion in emerging economies. As these regions experience economic growth, urbanization, and improvements in healthcare infrastructure, there is a growing demand for affordable medications to address the healthcare needs of expanding populations. Branded generics, with their established brand recognition and quality assurance, are well-positioned to capitalize on this opportunity by catering to the needs of patients in emerging markets and partnering with local distributors and healthcare providers to enhance market penetration.

Branded Generics Market Segmentation

By Drug Class
Alkylating Agents
Antimetabolites
Hormones
Anti-Hypertensive
Lipid Lowering Drugs
Anti-Depressants
Anti-Psychotics
Anti-Epileptics
Others
By Application
Oncology
Cardiovascular Diseases
Neurological Diseases
Gastrointestinal Diseases
Dermatological Diseases
Acute and Chronic Pain
Others
By Route of Administration
Topical
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Branded Generics Market Companies

Apotex Inc
Dr. Reddy's Laboratories Ltd
Endo International plc
GlaxoSmithKline plc
Lupin
Pfizer Inc
Sanofi
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Viatris Inc

 

 

Reasons to Buy the Branded Generics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Branded Generics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Branded Generics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

 

TABLE OF CONTENTS

1 Introduction to 2024 Branded Generics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Branded Generics Market Size Outlook, $ Million, 2021 to 2030
3.2 Branded Generics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Branded Generics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Branded Generics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Branded Generics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Branded Generics Market Industry
4.2 Key Market Trends in Branded Generics Market Industry
4.3 Potential Opportunities in Branded Generics Market Industry
4.4 Key Challenges in Branded Generics Market Industry

5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Branded Generics Market Share by Company (%), 2023
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Branded Generics Market Outlook By Segments
7.1 Branded Generics Market Outlook by Segments
By Drug Class
Alkylating Agents
Antimetabolites
Hormones
Anti-Hypertensive
Lipid Lowering Drugs
Anti-Depressants
Anti-Psychotics
Anti-Epileptics
Others
By Application
Oncology
Cardiovascular Diseases
Neurological Diseases
Gastrointestinal Diseases
Dermatological Diseases
Acute and Chronic Pain
Others
By Route of Administration
Topical
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

8 North America Branded Generics Market Analysis And Outlook To 2030
8.1 Introduction to North America Branded Generics Markets in 2024
8.2 North America Branded Generics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Branded Generics Market size Outlook by Segments, 2021-2030
By Drug Class
Alkylating Agents
Antimetabolites
Hormones
Anti-Hypertensive
Lipid Lowering Drugs
Anti-Depressants
Anti-Psychotics
Anti-Epileptics
Others
By Application
Oncology
Cardiovascular Diseases
Neurological Diseases
Gastrointestinal Diseases
Dermatological Diseases
Acute and Chronic Pain
Others
By Route of Administration
Topical
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

9 Europe Branded Generics Market Analysis And Outlook To 2030
9.1 Introduction to Europe Branded Generics Markets in 2024
9.2 Europe Branded Generics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Branded Generics Market Size Outlook By Segments, 2021-2030
By Drug Class
Alkylating Agents
Antimetabolites
Hormones
Anti-Hypertensive
Lipid Lowering Drugs
Anti-Depressants
Anti-Psychotics
Anti-Epileptics
Others
By Application
Oncology
Cardiovascular Diseases
Neurological Diseases
Gastrointestinal Diseases
Dermatological Diseases
Acute and Chronic Pain
Others
By Route of Administration
Topical
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

10 Asia Pacific Branded Generics Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Branded Generics Markets in 2024
10.2 Asia Pacific Branded Generics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Branded Generics Market size Outlook by Segments, 2021-2030
By Drug Class
Alkylating Agents
Antimetabolites
Hormones
Anti-Hypertensive
Lipid Lowering Drugs
Anti-Depressants
Anti-Psychotics
Anti-Epileptics
Others
By Application
Oncology
Cardiovascular Diseases
Neurological Diseases
Gastrointestinal Diseases
Dermatological Diseases
Acute and Chronic Pain
Others
By Route of Administration
Topical
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

11 South America Branded Generics Market Analysis And Outlook To 2030
11.1 Introduction to South America Branded Generics Markets in 2024
11.2 South America Branded Generics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Branded Generics Market size Outlook by Segments, 2021-2030
By Drug Class
Alkylating Agents
Antimetabolites
Hormones
Anti-Hypertensive
Lipid Lowering Drugs
Anti-Depressants
Anti-Psychotics
Anti-Epileptics
Others
By Application
Oncology
Cardiovascular Diseases
Neurological Diseases
Gastrointestinal Diseases
Dermatological Diseases
Acute and Chronic Pain
Others
By Route of Administration
Topical
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

12 Middle East And Africa Branded Generics Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Branded Generics Markets in 2024
12.2 Middle East and Africa Branded Generics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Branded Generics Market size Outlook by Segments, 2021-2030
By Drug Class
Alkylating Agents
Antimetabolites
Hormones
Anti-Hypertensive
Lipid Lowering Drugs
Anti-Depressants
Anti-Psychotics
Anti-Epileptics
Others
By Application
Oncology
Cardiovascular Diseases
Neurological Diseases
Gastrointestinal Diseases
Dermatological Diseases
Acute and Chronic Pain
Others
By Route of Administration
Topical
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Apotex Inc
Dr. Reddy's Laboratories Ltd
Endo International plc
GlaxoSmithKline plc
Lupin
Pfizer Inc
Sanofi
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Viatris Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug Class
Alkylating Agents
Antimetabolites
Hormones
Anti-Hypertensive
Lipid Lowering Drugs
Anti-Depressants
Anti-Psychotics
Anti-Epileptics
Others
By Application
Oncology
Cardiovascular Diseases
Neurological Diseases
Gastrointestinal Diseases
Dermatological Diseases
Acute and Chronic Pain
Others
By Route of Administration
Topical
Oral
Parenteral
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy